CB-5083: Selective p97 Inhibitor for Protein Homeostasis Disruption

Principle Overview: CB-5083 and the Disruption of Protein Homeostasis

CB-5083 is a highly selective, potent, and orally bioavailable inhibitor of the AAA ATPase p97 (valosin-containing protein). As a master regulator of protein homeostasis, p97 orchestrates protein degradation, organelle membrane fusion, and endosomal cargo sorting. Mechanistically, CB-5083 binds to and selectively inhibits the second ATPase domain of p97 (IC₅₀ = 15.4 nM), competing with ATP and inducing dose-dependent cytosolic protein degradation and apoptosis across multiple cancer cell lines, including HEK293T, A549, and HCT116. In vivo, CB-5083 demonstrates robust tumor growth inhibition in mouse xenograft models of lung carcinoma, colorectal adenocarcinoma, and multiple myeloma, while activating the unfolded protein response (UPR) and caspase signaling pathways.

Recent advances in ER quality control and lipid homeostasis research—such as the study by Carrasquillo Rodríguez et al. (2024)—underscore the centrality of p97 in proteasomal protein degradation and the unfolded protein response. By targeting the protein degradation pathway and AAA ATPase signaling, CB-5083 enables researchers to dissect the mechanistic crosstalk between protein and lipid homeostasis in both cancer and metabolic disease models.

Step-by-Step Experimental Workflow: Maximizing CB-5083 Utility

1. Compound Preparation and Storage

• Obtain high-purity CB-5083 from a trusted supplier such as APExBIO to ensure experimental reproducibility.
• CB-5083 is a solid with a molecular weight of 413.47. It is insoluble in water but readily dissolves in DMSO (≥20.65 mg/mL) or ethanol (≥4.4 mg/mL). Prepare concentrated stocks (e.g., 10 mM in DMSO), aliquot, and store at –20°C. Avoid repeated freeze-thaw cycles and long-term storage of diluted solutions.

2. In Vitro Cellular Assays

• Determine optimal CB-5083 concentrations for your cell line. Literature reports effective induction of protein homeostasis disruption and apoptosis in HEK293T, A549, and HCT116 cells at sub-micromolar concentrations.
• Treat cells with a dilution series (e.g., 5 nM to 2 μM) to establish dose-response curves for endpoints such as cell viability (MTT/XTT), activation of the unfolded protein response (CHOP, BiP markers), and caspase activation (Caspase-Glo assays).
• For ER stress and protein degradation studies, co-stain for UPR markers and proteasome activity (e.g., using MG-132 as a positive control).

3. In Vivo Tumor Xenograft Study Design

• Implant human tumor cells (lung carcinoma, colorectal adenocarcinoma, or multiple myeloma) into immune-compromised mice.
• Administer CB-5083 orally at previously validated effective doses (e.g., reported preclinical regimens range from 10–60 mg/kg/day), monitoring for tumor volume reduction and animal weight.
• Collect tumor tissue for downstream analyses: UPR activation (qPCR, Western blot for BiP, CHOP), apoptosis (TUNEL or cleaved caspase-3 staining), and protein degradation markers (ubiquitinated protein accumulation).

4. Lipid Homeostasis and ER Regulation Assays

• Leverage CB-5083 to probe ER-associated degradation (ERAD) and lipid synthesis, building on the findings by Carrasquillo Rodríguez et al. (2024) exploring the interplay between p97, proteasome function, and ER expansion.
• Combine CB-5083 treatment with lipidomics or confocal imaging of ER/nuclear envelope to assess changes in membrane biogenesis and lipid droplet formation.

Advanced Applications and Comparative Advantages

Unraveling Protein Quality Control and UPR Pathways

CB-5083’s selective targeting of p97 allows for precise disruption of protein homeostasis. By blocking the AAA ATPase signaling pathway, CB-5083 induces accumulation of misfolded proteins, triggers the ER stress response, and activates the unfolded protein response (UPR) pathway—a cascade that culminates in cancer cell apoptosis via the caspase signaling pathway.

This mechanistic specificity sets CB-5083 apart from less selective proteasome inhibitors. For example, compared to broad-spectrum agents like MG-132, CB-5083 enables researchers to pinpoint p97-dependent branches of the protein degradation pathway without inducing global proteasome shutdown, thereby reducing off-target toxicity in experimental models.

Translational Impact in Cancer Research

CB-5083’s oral bioavailability and pharmacodynamic profile have propelled it to phase 1 clinical trials for multiple myeloma and solid tumors. In preclinical mouse xenograft studies, CB-5083 demonstrates significant tumor growth inhibition and robust induction of apoptosis markers, validating its utility in translational cancer research. This positions CB-5083 as a benchmark tool for dissecting tumor xenograft growth inhibition and for studying the therapeutic potential of selective p97 ATPase inhibitors in oncology.

Integration with Lipid Metabolism and ER Stress Models

Recent work (see Carrasquillo Rodríguez et al., 2024) highlights the nuanced regulatory roles of p97 and associated ER quality control factors in lipid synthesis and storage. By combining CB-5083 with genetic or pharmacological perturbations of lipid regulators (e.g., CTDNEP1, NEP1R1, lipin 1), investigators can systematically dissect the intersection of protein and lipid homeostasis—enabling new insights into metabolic adaptation in cancer and metabolic disease models.

Comparative Knowledge Landscape

• Precision Disruption of Protein Homeostasis: This review complements our workflow focus by providing mechanistic insights into CB-5083's unique role in dissecting ER quality control and lipid homeostasis.
• CB-5083: Precision Disruption of Protein and Lipid Homeostasis: Extends the discussion by exploring advanced cancer applications where CB-5083’s dual effect on protein and lipid regulation is therapeutically leveraged.
• CB-5083 and the Next Frontier of Protein Homeostasis Disruption: Contrasts standard tool compounds with CB-5083’s selectivity, underlining its value for future oncology research and experimental precision.

Troubleshooting and Optimization Tips

Solubility and Dosing Challenges

• Solubility: CB-5083 is insoluble in water. Always dissolve in DMSO or ethanol at recommended concentrations; vortex thoroughly and, if necessary, sonicate to ensure complete dissolution. Filter sterilize using a low-protein binding membrane for cell-based assays.
• Solution Stability: Prepare fresh working solutions prior to each experiment. Long-term storage of diluted CB-5083 can result in compound degradation and loss of activity.

Optimizing Cellular Assays

• Cell Line Variability: Sensitivity to CB-5083 can vary by cell type and passage number. Perform preliminary dose-response studies for each new batch of cells. For example, IC₅₀ values may shift in resistant lines or after long-term culture.
• Assay Timing: Protein degradation and apoptosis induction can be time-dependent. Short exposure (4–8 hours) may reveal early UPR activation, while longer treatments (24–48 hours) are optimal for cell death readouts.

In Vivo Study Considerations

• Oral Bioavailability: Formulate CB-5083 in a vehicle compatible with oral gavage (e.g., 0.5% methylcellulose with 0.1% Tween-80) to ensure consistent dosing in xenograft models.
• Toxicity Monitoring: Although CB-5083 is selective, high doses may elicit off-target toxicity. Monitor animal weight, liver enzymes, and histopathology. Titrate dose to balance efficacy with tolerability.

Data Interpretation and Off-Target Effects

• Include appropriate controls: vehicle-only, unrelated ATPase inhibitors, and genetic perturbations (e.g., p97 knockdown/knockout) to confirm on-target effects.
• Monitor for compensatory UPR or autophagy activation, as cells may adapt to chronic protein homeostasis disruption.

Future Outlook: Expanding the Horizons of p97 Inhibition

CB-5083’s transition from bench to bedside, exemplified by its phase 1 clinical evaluation in multiple myeloma and solid tumors, signals a new era for selective p97 ATPase inhibitors in translational medicine. As structural and functional analyses of ER quality control networks advance—such as those dissecting the CTDNEP1-NEP1R1 complex (Carrasquillo Rodríguez et al., 2024)—CB-5083 will remain central for interrogating the intersection of protein degradation, UPR, and metabolic adaptation.

Emerging applications include combining CB-5083 with agents targeting lipid metabolism, immunoproteasome function, or autophagy, as well as CRISPR-based screens to map synthetic lethal interactions in cancer cells. Continued comparative analyses, as highlighted in leading reviews and tool compound assessments, will further clarify CB-5083’s advantages and guide protocol refinement.

For researchers seeking a rigorously validated, selective, and orally bioavailable p97 inhibitor, APExBIO’s CB-5083 stands as the benchmark for dissecting protein homeostasis disruption, cancer cell apoptosis induction, and tumor xenograft growth inhibition in preclinical and translational models.